PROSPECTUS SUPPLEMENT
(To Prospectus dated November 1, 1996)


                        MEDIMMUNE, INC.

         $60,000,000 Principal Amount of 7% Convertible
                  Subordinated Notes due 2003
            (Interest payable January 1 and July 1)

                3,048,780 Shares of Common Stock
                    ______________________________
                                   
     This document supplements the Prospectus dated November 1, 1996
relating to (i) $60,000,000 aggregate principal amount of 7%
Convertible Subordinated Notes due 2003 (the "Notes") of MedImmune,
Inc., a Delaware corporation (the "Company"), and (ii) 3,048,780 shares
of Common Stock of the Company which are initially issuable upon
conversion of the Notes plus such additional indeterminate number of
shares of Common Stock of the Company as may become issuable upon
conversion of the Notes as a result of adjustments to the conversion
price (the "Shares").  The Notes and the Shares are being offered for
the account of the holders thereof. The Notes were initially acquired
from the Company by Morgan Stanley & Co. Incorporated in July 1996 in
connection with a private offering.  This Prospectus Supplement is
incorporated by reference into the Prospectus, and all terms used
herein shall have the meaning assigned to them in the Prospectus.  On
July 21, 1997 the closing price of the Common Stock of the Company on
the Nasdaq National Market was $23.50. The Common Stock of the Company
is traded under the symbol "MEDI."

     Selling Securityholder:            Delaware State Employee
                                   Retirement Fund
                                   c/o Mercantile Bank
                                   2 Hopkins Plaza
                                   Baltimore, Maryland  21201

                                   Securities Being Sold:
                                   $600,000 aggregate principal amount
                                   of 7% Convertible Subordinated Notes
                                   due 2003

     Price:                        142.75%

     Participating Broker-Dealer:  Morgan Stanley

     Commission or Compensation:   None

     As of July 18, 1997 and prior to giving effect to the sale of the
Notes being offered by the Selling Securityholder hereby, the Selling
Securityholder beneficially owned $2,500,000 aggregate principal amount
of Notes, representing approximately 4.2% of the Notes outstanding as
of such date.  As of such date, the Selling Securityholder did not
beneficially own any shares of Common Stock of the Company, other than
the shares of Common Stock into which the Notes beneficially owned by
the Selling Securityholder are convertible.

                        _______________________

SEE "RISK FACTORS" BEGINNING ON PAGE 3 OF THE ACCOMPANYING PROSPECTUS
FOR A DESCRIPTION OF CERTAIN FACTORS THAT SHOULD BE CONSIDERED BY
PROSPECTIVE INVESTORS.

                        _______________________

     THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE
      SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES
       COMMISSION NOR HAS THE SECURITIES AND EXCHANGE COMMISSION
          OR ANY STATE SECURITIES COMMISSION PASSED UPON THE
             ACCURACY OR ADEQUACY OF THIS PROSPECTUS.  ANY
                    REPRESENTATION TO THE CONTRARY
                        IS A CRIMINAL OFFENSE.

                        _______________________


The date of this Prospectus Supplement is July 22, 1997.